YCW25· AI· DevtoolsDelineate
Agents for Accelerated Clinical Trial Design
Founders
- Emily NievesFounder/CEO
- Jawad IqbalFounder/CTO
Same space
Competitors
Closest in what they build, same category.
Adjacent
Overlapping tags, a different niche.
MiracleW23Accelerate clinical trials with real-time, actionable insightsShared: biotechActive
ConvexiaS25The world's first AI-maximalist pharma companyShared: biotechActive
Lavo Life SciencesW23AI for drug formulationShared: biotechInactive
Parallel BioS21Using the immune system to cure diseaseShared: biotechActive
PanoptiveS25The continuous oversight engine for clinical trialsShared: biotechActive
Also from W25 in AI
Batchmates in Winter 2025.
Exin TherapeuticsW25AI drug discovery platform for neurotherapeuticsActive
.WaveW25Continuous inference for streaming AI modelsActive
10xW25AI Sales Teams for Dental PracticesActive
a0.devW25We make mobile apps using AI.Active
A1Zap by A1BaseW25The social network layer for AI appsActive
AdamW25AI Powered CADActive
About Delineate
Delineate is building AI agents to design better clinical trials faster. This is a $10B dollar market, where saving even 1 day along the process is equal to $1-5M in revenue potential. We process existing clinical trial research into specialized datasets saving scientists months of effort. Delineate is working with two of the largest pharmaceutical companies. With one of our customers, we are helping them get to the next phase of trials faster by creating the largest dataset on a drug class ever constructed.
Boston, MA, USA; Remote
Delineate: questions
Which YC batch was Delineate in?
Delineate was in Y Combinator's Winter 2025 batch (W25).
Is Delineate still active?
Y Combinator lists Delineate as active.
Who founded Delineate?
Delineate's founders, as listed on its YC page: Emily Nieves (Founder/CEO), Jawad Iqbal (Founder/CTO).
Where is Delineate based?
Delineate lists Boston, MA, USA; Remote as its location on YC's directory.
Not affiliated with Y Combinator. From YC's public directory. Logos via logo.dev; trademarks belong to their owners.